China Biotech Services Holdings Limited expects to report a net profit of no less than HK$15.00 million for the six months ended 30 June 2026, according to a positive profit alert filed with Hong Kong’s GEM board. The projection marks a sharp turnaround from the HK$37.00 million net loss recorded in the comparable 2025 period.

Management attributes the swing primarily to an estimated HK$77.00 million–HK$87.00 million non-cash, unrealised fair-value gain on the Group’s outstanding convertible bonds. This uplift more than offsets two key drags:

1. Finance costs have risen by about HK$9.00 million following the issuance of US$35 million in new convertible bonds in February 2026. 2. The current period lacks a one-off HK$14.00 million insurance compensation booked as other income in first-half 2025.

The unaudited figures are based on internal management accounts and have yet to be reviewed by the Company’s audit committee. Formal interim results are slated for release in late August 2026.

Investors are advised to exercise caution when dealing in the Company’s shares until the final results are published.